Sanara MedTech terminates Catalyst advisory agreement; shifts to soft tissue/bone fusion strategy

Sanara MedTech Inc.

On June 2, 2026, Sanara MedTech and The Catalyst Group mutually terminated their March 2023 advisory agreement.
Termination due to shift in strategy to focus on soft tissue repair and bone fusion surgical products.
No fee or penalty paid in connection with termination; certain covenants (indemnification, confidentiality) remain in effect.
Chairman Ronald T. Nixon is founder/managing partner of Catalyst and holds >5% beneficial ownership of Sanara MedTech.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sanara MedTech Inc. terminated Services Agreement with The Catalyst Group, Inc. (effective 2026-06-02).

Action: termination
Counterparty: The Catalyst Group, Inc.
Effective: 2026-06-02

Exact text from the filing

On June 2, 2026, in connection with the Company’s shift in strategy to focus on soft tissue repair and bone fusion products for the surgical market, the Company entered into a Mutual Termination Agreement (the “Mutual Termination Agreement”) with Catalyst, pursuant to which the parties agreed to terminate the Services Agreement, effective immediately.

View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.